Australia's most trusted source of pharma news
Friday, 16 November 2018
Lost Your Access?
Maviret makes its mark
Newcomer already impacting PBS Hep C market.
Pfizer's Lyrica patent pain
UK judgement could open way to $900 million payback.
Job growth winners and losers
Who added, who cut in 2017-18 and by how much.
CSL gender report card fail
Growing fast but making slow progress on equality.
Aust Phebra opens UK branch
Submits new applications to UK regulators.
Pfizer CBD move delayed
Exclusive first pics of new city digs show not yet ready.
Pharma hits pay gap roadblock
Better than most Aust sectors but progress has stalled.
Is Aimovig Novartis' headache?
Future of migraine biologic murky as competitors threaten.
PBS 2018 newbies start big
New and expanded listings rack up $180m to Q3.
Apotex CFO jumps ship
Pharma veteran heads to medicinal cannabis start-up.
Aust docs get I-O sneak peak
Hundreds attend Perth cancer meet-up this week.
Pharmas do cancer shuffle
Prediction to 2024 names future winners and losers.
Aust pharma female CEOs up
Proportion of bosses doubles but direct reports mostly male.
Ex-GSK execs sign US deal
Melbourne-based pharma inks USD12.5m deal with Aurobindo.
CWH tipped for ASX in 2019
Float rumours rife with reports chemist giant worth $8b+.
US, EU moves in COPD
Mylan enters market as GSK expands presence.
PBAC status quo threatened
Committee changes come at crucial time.
Parkinson's drug passes muster
Follows major Nov PBAC submission.
Events & Conferences
© 2003 - 2018 Lush Media
Pharma in Focus
Jolly Good Design